PARSIPPANY, N.J. GlaxoSmithKline Consumer Healthcare on Thursday commended the Food and Drug Administration for holding a scientific workshop this week that focused on the risks and benefits associated with the long-term use of nicotine-replacement therapy products.
GSK, the manufacturer of smoking-cessation products NicoDerm and Nicorette, suggested the workshop is a first step in supporting language in the 2009 Family Smoking Prevention and Tobacco Control Act, which called upon the FDA to "consider approving the extended use of nicotine-replacement products — such as nicotine patches, nicotine gum and nicotine lozenge — for the treatment of tobacco dependence."
As a result of the FDA's review of long-term use, GSK has submitted a statement into the FDA public docket on its position regarding the long-term use of NRT. GSK believes that using NRT products to quit smoking is far safer than continuing to smoke. NRT products offer a step-down therapy that doubles a smoker's chances of quitting versus attempting to quit smoking “cold turkey.” Additionally, several other countries already encourage the use of NRT products for longer durations to keep people tobacco-free.
Smoking is the No. 1 preventable cause of disease and death in the United States. More than 46 million Americans smoke. Research indicated about 70% of smokers want to quit at any given time, but the success rates remain suboptimal. Tobacco use causes more than 400,000 deaths in the United States each year, and approximately 8.6 million Americans have chronic illnesses related to smoking.